19. Sepsis-Induced Cardiomyopathy

Quick Recap

Cross-cutting protocol — companion to Vasopressor & Inotrope Selection & Titration and Septic Shock (revised) protocols. Addresses a genuinely under-consolidated diagnostic entity — sepsis-induced cardiomyopathy still lacks a formal, universally accepted consensus definition four decades after its original description — with a specifically counterintuitive prognostic finding: pooled meta-analytic data show no difference in ejection fraction between sepsis survivors and non-survivors, directly challenging the intuitive assumption that a lower EF signals worse prognosis.

1. Definition

Sepsis-induced cardiomyopathy (SICM) — also termed septic cardiomyopathy or sepsis-associated cardiomyopathy: first described by Parker et al. in 1984 as a reversible myocardial depression occurring in septic shock — classically characterized by three features: left ventricular dilatation, depressed ejection fraction, and recovery within 7–10 days.

No formal, universally accepted consensus definition currently exists — a genuinely important, explicitly acknowledged limitation of this entire field. Recent literature specifically states the field "has been hampered by lack of consensus about its proper definition, with a great deal of heterogeneity in clinical trial data...and consequent disparity of estimates of incidence, prognosis, and clinical significance" — and, notably, "new diagnostic techniques, while potentially shedding light on pathophysiology, have only exacerbated these challenges" rather than resolving them, as more sensitive echocardiographic tools have revealed a broader, more heterogeneous spectrum of cardiac dysfunction than the original, simpler depressed-EF description captured.

The expanding phenotypic spectrum: beyond the classically described depressed LV systolic function, contemporary echocardiographic techniques (particularly speckle-tracking-derived global longitudinal strain) have revealed that sepsis-associated myocardial dysfunction also encompasses LV diastolic dysfunction, supranormal/hyperdynamic LV systolic states, and right ventricular dysfunction/injury — occurring independently or in combination, and each phenotype remains underrecognized and understudied relative to the classically described depressed-EF presentation.

2. Pathophysiology

SICM's pathophysiology involves multiple, incompletely characterized, overlapping mechanisms: inflammatory cytokines (endotoxin, TNF-α, IL-6, and other mediators directly depressing myocardial contractility), mitochondrial dysfunction impairing cardiomyocyte energy production, altered coronary microcirculation (distinct from epicardial coronary artery disease, which is specifically excluded from the SICM diagnosis by definition), and nitric oxide-mediated effects on cardiac and vascular tone — together producing a functionally and structurally injured myocardium that is, per the classic description, expected to recover as the underlying septic process resolves.

Why loading conditions specifically complicate the assessment of "true" cardiac dysfunction in sepsis: LV ejection fraction, the parameter most commonly used to describe cardiac function in this literature, is inherently dependent on loading conditions — particularly afterload — which fluctuate dramatically over the course of septic shock resuscitation (vasopressor titration, fluid administration, and the shock state itself all directly alter afterload) — this limits EF's validity as a measure of intrinsic myocardial contractility in this specific, hemodynamically unstable population, motivating the field's move toward load-independent or less-load-dependent measures like global longitudinal strain (Section 9).

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses a diagnostic and prognostic framework applied within the broader septic shock resuscitation course rather than a standalone stabilization scenario; cross-reference Septic Shock (revised) and Vasopressor & Inotrope Selection & Titration protocols for the acute management framework SICM assessment sits within.

Checklist:

4. Focused History

• Baseline cardiac history and function, essential for confirming the "new" nature of the observed dysfunction and excluding pre-existing structural heart disease as the primary explanation
• Timeline of hemodynamic instability relative to septic shock onset
• Cardiac risk factors relevant to the acute coronary syndrome exclusion

5. Comprehensive System-wise Examination

• Cardiovascular: hemodynamic trajectory, response to fluid/vasopressor therapy — SICM is classically described as "poorly responsive to fluid and catecholamines", a clinical clue distinguishing it from simple volume-responsive distributive shock

POCUS integration: central to this entire protocol — see Section 9/10.

6. Syndrome Identification — Reframed as Phenotypic Classification

• Classic depressed-EF phenotype: LV dilatation with reduced systolic function, poorly responsive to fluid/catecholamines, expected reversibility within 7–10 days — the originally described, most historically studied presentation
• Diastolic dysfunction phenotype: increasingly recognized as common and prognostically relevant, though less studied than the systolic phenotype
• Supranormal/hyperdynamic phenotype: an ejection fraction higher than normal — a genuinely counterintuitive presentation within the broader "cardiac dysfunction in sepsis" framework, since a hyperdynamic state is not intuitively thought of as "dysfunction," yet is increasingly recognized as carrying independent prognostic significance
• RV dysfunction/injury: increasingly recognized as occurring independently of, or alongside, LV involvement, with its own distinct prognostic significance (Section 8)

7. Differential Diagnosis

Must-not-miss (specifically excluded by SICM's definitional framework):

• Acute coronary syndrome: a defining exclusion — SICM is by definition not caused by ACS, requiring active consideration and exclusion, particularly given sepsis's own capacity to produce troponin elevation independent of true coronary ischemia
• Takotsubo (stress) cardiomyopathy: a related but distinct entity, classically involving mid-to-apical LV contractile dysfunction with a different, more specific regional wall-motion pattern than SICM's typically more global dysfunction
• Tachycardia-mediated cardiomyopathy: relevant particularly in prolonged, poorly-rate-controlled septic shock with persistent tachycardia (cross-reference Beta-Blockade in Septic Shock protocol for the specific, cautionary evidence regarding deliberately treating this via beta-blockade)
• Recurrent or unrecognized pulmonary embolism: a specific alternative explanation for RV dysfunction and hemodynamic compromise that should be actively considered, particularly when RV dysfunction is the dominant echocardiographic finding

Diagnostic approach: as illustrated in a recent case report specifically working through this exact differential, the diagnosis of SICM is supported by temporal association with septic shock onset, echocardiographic abnormalities emerging contemporaneously with sepsis/bacteremia, and — critically — improvement in parallel with hemodynamic stabilization and infection clearance — the trajectory of recovery alongside sepsis resolution is itself a key diagnostic confirming feature, not simply the presence of dysfunction at a single timepoint.

8. Severity/Risk Assessment — A Genuinely Counterintuitive Prognostic Picture

LVEF as a prognostic marker — a striking, counterintuitive negative finding: a recent meta-analysis on sepsis-induced ventricular dysfunction found no difference in ejection fraction between survivors and non-survivors — directly challenging the intuitive clinical assumption that a lower EF in septic shock signals worse prognosis. This is a genuinely important, easily-overlooked finding: the degree of LV systolic depression itself does not appear to reliably predict mortality, complicating any straightforward "worse EF = worse outcome" clinical framing that might otherwise seem obvious.

RV dysfunction — a more consistent, independently prognostic finding: in contrast to the LVEF-mortality dissociation above, a dedicated meta-analysis (Vallabhajosyula et al., 1,373 patients) found RV dysfunction carries genuine, independent prognostic significance for both short- and long-term mortality in sepsis — suggesting that RV involvement specifically, rather than LV systolic depression per se, may be the more clinically meaningful echocardiographic marker of risk in this population.

Troponin I: elevated troponin I has been independently associated with higher mortality risk in septic patients, offering a complementary, biomarker-based prognostic tool alongside echocardiographic assessment.

Global longitudinal strain (GLS) and mortality: a 2024 updated systematic review and meta-analysis with trial sequential analysis specifically examined mortality in septic cardiomyopathy identified by longitudinal strain via speckle-tracking echocardiography — reflecting the field's ongoing effort to identify a more reliably prognostic echocardiographic parameter than conventional LVEF, given the LVEF-mortality dissociation noted above.

9. Investigations

Troponin I: as noted in Section 8, an independent mortality predictor; also useful adjunctively in the ACS-exclusion differential, interpreted with the caveat that sepsis itself commonly produces troponin elevation independent of true coronary ischemia.

Repeated echocardiographic evaluation: explicitly described as "mandatory" given the dynamic, loading-condition-dependent nature of cardiac function assessment in evolving septic shock — a single echocardiogram provides only a loading-condition-specific snapshot, not necessarily a reliable characterization of "true" underlying myocardial function.

10. Point-of-Care Ultrasound — The Central Diagnostic Modality

Standard LVEF assessment: the most commonly used parameter historically, but with the specific, acknowledged limitation (Section 2) that its dependence on loading conditions, particularly afterload, limits its validity as a measure of true intrinsic myocardial contractility in the hemodynamically unstable septic shock population.

Global longitudinal strain (GLS) via speckle-tracking echocardiography: increasingly favored as potentially more sensitive and specific for septic cardiomyopathy than conventional LVEF, given its comparatively reduced (though not eliminated) load-dependency — representing the field's current best answer to LVEF's specific prognostic-value limitation noted in Section 8.

Ventriculo-arterial coupling: an emerging, more comprehensive hemodynamic parameter supplementing traditional LVEF and other conventional measures, reflecting the interaction between cardiac contractility and the arterial (afterload) system the heart is working against — particularly relevant given afterload's central role in confounding simple LVEF interpretation in this population.

Cardiovascular clusters/phenotyping via combined clinical and echocardiographic parameters: a post hoc analysis (Geri et al., Intensive Care Med 2019) specifically examined combining clinical and echocardiographic data to identify distinct cardiovascular phenotypes/clusters within septic shock — reflecting the field's broader move toward more nuanced, multi-parameter phenotyping rather than a single-metric (LVEF-based) classification.

11. Evidence-Based Management — Genuinely Limited, Non-Specific

There are few persuasive data to suggest that decreased ejection fraction from sepsis-induced cardiomyopathy merits a treatment strategy different from other causes of reduced EF — a direct, explicit conclusion from recent dedicated review literature — except that improvement may be more likely, given the classic description's emphasis on reversibility over 7–10 days. This is a genuinely important, somewhat sobering practical conclusion: despite decades of research characterizing this entity's pathophysiology and echocardiographic phenotypes in increasing detail, no SICM-specific therapeutic strategy has been demonstrated to improve outcomes beyond standard sepsis/septic shock management.

Standard management (cross-reference Septic Shock and Vasopressor & Inotrope Selection & Titration protocols):

• Etiological treatment (source control and antimicrobial therapy) as the primary, foundational intervention — SICM is a downstream manifestation of the underlying septic process, not an independently treatable target
• Adapted fluid resuscitation, informed by the recognition that SICM-affected hearts may be poorly fluid-responsive
• Vasopressor use per standard septic shock protocols
• Inotrope use remains genuinely uncertain: current literature explicitly states inotrope use "remains uncertain" as a strategy specifically for SICM, without robust evidence supporting a specific inotropic approach targeted at the cardiomyopathy itself, distinct from standard hemodynamic support principles
• Heart rate control "could be an option in some patients": a notably hedged, uncertain statement — cross-reference Beta-Blockade in Septic Shock protocol for the specific, cautionary evidence (STRESS-L's harm signal) that should inform genuine caution before pursuing this approach, given that protocol's finding that deliberate beta-blockade for persistent tachycardia in septic shock was associated with a trend toward harm, not benefit, in the most rigorous available trial

Practical synthesis: SICM should currently be understood primarily as a diagnostic and prognostic framework for characterizing and monitoring cardiac involvement in septic shock, rather than as an entity warranting a distinct, SICM-specific therapeutic pathway — standard sepsis/septic shock management remains the appropriate approach regardless of which SICM phenotype (or combination) is identified, with echocardiographic monitoring serving primarily to inform hemodynamic management (fluid responsiveness, vasopressor/inotrope titration per Vasopressor & Inotrope Selection & Titration and Fluid Responsiveness & Hemodynamic Assessment protocols) rather than to trigger a separate, cardiomyopathy-specific treatment algorithm.

12. Organ Support

Directly interacts with Vasopressor & Inotrope Selection & Titration and Fluid Responsiveness & Hemodynamic Assessment protocols — SICM's echocardiographic findings should inform, not override, the standard hemodynamic management framework established in those protocols.

13. Disease-Specific Therapy — Not Established

No SICM-specific pharmacotherapy has been established as beneficial beyond standard septic shock management (Section 11); cross-reference Vasopressor & Inotrope Selection & Titration and Corticosteroids in Septic Shock & Critical Illness protocols for the relevant standard therapeutic frameworks.

14. Consultation Matrix

15. Monitoring Framework

• Echocardiographic: repeated, serial evaluation given the dynamic, loading-condition-dependent nature of findings — not a single-timepoint assessment
• Biomarker: troponin I trend as an adjunct prognostic and diagnostic tool
• Clinical trajectory: the classic 7–10-day reversibility window as an expected recovery timeline, with failure to improve within this window prompting reconsideration of the diagnosis or search for an alternative/additional explanation

16. ICU Bundle Checklist

17. Complications

Cross-reference Septic Shock (revised) protocol for the broader complication profile of septic shock itself; SICM represents a manifestation of, rather than a separate complication from, this underlying process.

Persistent dysfunction beyond the classic 7–10-day recovery window: should prompt reconsideration of the diagnosis (alternative or additional cardiac pathology) rather than assuming indefinite SICM persistence, given the reversibility criterion is central to the classic definition.

18. Escalation & De-escalation — Not Directly Applicable

Cross-reference Vasopressor & Inotrope Selection & Titration protocol for the relevant hemodynamic escalation/de-escalation framework this diagnostic entity informs but does not independently drive.

19. ICU Discharge Criteria — Not Directly Applicable

Cross-reference ICU Discharge Criteria & Step-Down protocol; cardiac function trajectory and expected recovery timeline should be communicated at care transitions where relevant.

20. Documentation & Medicolegal Checklist

• Echocardiographic phenotype(s) identified and documented, with serial reassessment results
• Alternative diagnoses (ACS, Takotsubo, PE) actively considered and excluded, documented
• Trajectory of cardiac function relative to overall sepsis resolution documented, supporting or challenging the SICM diagnosis

21. Key Guidelines

• No dedicated SICM-specific management guideline exists independent of standard Surviving Sepsis Campaign guidance (cross-reference Septic Shock and Sepsis Bundles & Source Control protocols), consistent with the absence of a demonstrated SICM-specific treatment strategy

22. Landmark Studies

23. Controversies

• The absence of a formal, consensus definition after four decades is itself a genuine, foundational limitation worth stating explicitly, not glossing over: this protocol treats SICM's definitional heterogeneity as the root cause of much of the field's disparate incidence, prognosis, and treatment-response literature — comparing studies that use different diagnostic criteria for what they each call "sepsis-induced cardiomyopathy" is comparing genuinely different, only partially overlapping patient populations, complicating any confident synthesis of this literature.
• The LVEF-mortality dissociation is a genuinely important, easily overlooked finding that argues against a simple, intuitive clinical framing: the finding that EF does not differ between survivors and non-survivors should specifically caution against treating a depressed EF discovered on echocardiography in septic shock as an independently ominous finding warranting escalated concern or intervention beyond standard septic shock management — the more consistently prognostic finding (RV dysfunction) points toward a different, more specific echocardiographic focus than the traditionally emphasized LV systolic function.
• "New diagnostic techniques have only exacerbated these challenges" is a striking, explicitly stated observation worth taking seriously: rather than resolving the field's definitional and prognostic uncertainty, more sensitive tools (speckle-tracking, GLS, multi-phenotype clustering) have revealed a more complex, heterogeneous picture than the original simple depressed-EF description — this is not necessarily a failure of these newer tools, but a genuine reflection of how much heterogeneity the classic, simpler definition had been obscuring; this protocol treats this increasing complexity honestly rather than implying the field has converged toward a clearer picture over time.
• The absence of a demonstrated SICM-specific treatment strategy, despite extensive pathophysiological and diagnostic characterization, is a genuine, practically important limitation: this protocol explicitly avoids implying that better diagnostic characterization (more sensitive echocardiographic phenotyping) has translated into better, more targeted treatment — it has not, to date, and standard sepsis management remains the appropriate approach regardless of the specific cardiac phenotype identified.

24. References

1. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100(4):483-490.
2. Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care. 2015;3:48.
3. Sepsis-induced myocardial dysfunction: heterogeneity of functional effects and clinical significance. Front Cardiovasc Med. 2023;10:1200441.
4. Sepsis-Associated Cardiomyopathy: Long-Term Prognosis, Management, and Guideline-Directed Medical Therapy. Curr Cardiol Rep. 2024.
5. Sepsis-induced cardiomyopathy: mechanism, prevalence, and emerging phenotypes. Chest. 2025.
6. Septic cardiomyopathy: characteristics, evaluation, and management. Emerg Crit Care Med. 2022;2(3):135-147.
7. Septic cardiomyopathy: diagnosis and management. J Intensive Med. 2021.
8. Geri G, Vignon P, Aubry A, et al. Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters: a post hoc analysis. Intensive Care Med. 2019;45(5):657-667.
9. Vallabhajosyula S, Shankar A, Vojjini R, et al. Impact of right ventricular dysfunction on short-term and long-term mortality in sepsis: a meta-analysis of 1,373 patients. Chest. 2021.
10. Pruszczyk A, Zawadka M, Andruszkiewicz P, et al. Mortality in patients with septic cardiomyopathy identified by longitudinal strain by speckle tracking echocardiography: an updated systematic review and meta-analysis with trial sequential analysis. Anaesth Crit Care Pain Med. 2024;43(2):101339.
11. Transient sepsis-induced cardiomyopathy in the setting of alcohol withdrawal [case report illustrating diagnostic approach]. Cureus. 2026.
12. The Washington Manual of Critical Care, 4th ed. 2025 — sepsis and cardiovascular dysfunction chapters.
13. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant septic shock content.